Online inquiry

IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12274MR)

This product GTTS-WQ12274MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Systemic sclerosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12274MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3113MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ1454MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ9707MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ3367MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ176MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ10231MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4742MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ1466MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW